CN103768308A - Medicament composition for treating upper respiratory infections and preparation method thereof - Google Patents
Medicament composition for treating upper respiratory infections and preparation method thereof Download PDFInfo
- Publication number
- CN103768308A CN103768308A CN201410065107.4A CN201410065107A CN103768308A CN 103768308 A CN103768308 A CN 103768308A CN 201410065107 A CN201410065107 A CN 201410065107A CN 103768308 A CN103768308 A CN 103768308A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- upper respiratory
- pharmaceutical composition
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title abstract description 24
- 239000000203 mixture Substances 0.000 title abstract description 6
- 208000020029 respiratory tract infectious disease Diseases 0.000 title abstract 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000010231 banlangen Substances 0.000 claims abstract description 16
- 239000012528 membrane Substances 0.000 claims abstract description 16
- 229920001353 Dextrin Polymers 0.000 claims abstract description 15
- 239000004375 Dextrin Substances 0.000 claims abstract description 15
- 235000019425 dextrin Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241001522129 Pinellia Species 0.000 claims abstract description 4
- 241000555682 Forsythia x intermedia Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 230000008030 elimination Effects 0.000 claims description 20
- 238000003379 elimination reaction Methods 0.000 claims description 20
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 16
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000005550 wet granulation Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 235000006463 Brassica alba Nutrition 0.000 claims description 2
- 241000208296 Datura Species 0.000 claims description 2
- 241001180876 Saposhnikovia Species 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 241000220262 Sinapis alba Species 0.000 claims 1
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 11
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract description 10
- 229960002179 ephedrine Drugs 0.000 abstract description 10
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 2
- 229940041616 menthol Drugs 0.000 abstract 2
- 240000007175 Datura inoxia Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 29
- 206010011224 Cough Diseases 0.000 description 24
- 206010062717 Increased upper airway secretion Diseases 0.000 description 15
- 208000026435 phlegm Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 241000510654 Bupleurum chinense Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001871 benproperine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N methyl phenyl ether Natural products COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940095453 prednisone 10 mg Drugs 0.000 description 1
- 125000002324 prednisone group Chemical group 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament composition for treating upper respiratory infections and a preparation method thereof and belongs to the technical scheme of traditional Chinese medicine preparations. The medicament composition comprises the following raw materials in parts by weight: 40-50 parts of ephedrine, 20-30 parts of liquorice, 20-40 parts of radix isatidis, 10-20 parts of radix bupleuri, 5-10 parts of pinellia ternate, 5-10 parts of scutellaria baicalensis, 10-20 parts of dandelion, 5-10 parts of dried orange peel, 3-5 parts of platycodon grandiflorum, 4-8 parts of menthol, 3-5 parts of saposhnidoviae radix, 6-12 parts of fructus forsythia, 10-15 parts of hindu datura flower, 10-15 parts of semen brassicae and 30-50 parts of dextrin. Through drug synergism, the medicament composition is capable of effectively treating upper respiratory infections and relieving uncomfortable syndromes; meanwhile, as pinellia ternate is separately extracted, the extraction yield of ephedrine is effectively improved; menthol is treated through an ultrafiltration membrane, impurities are removed, thus the stability of ephedrine in a finished product is remarkably improved.
Description
Technical field
The invention discloses a kind of pharmaceutical composition that is used for the treatment of upper respiratory tract infection and preparation method thereof, belong to Chinese medicine preparation technical scheme.
Background technology
Upper respiratory tract infection refers to from nasal cavity to the acutely inflamed general name between throat, is modal infectious disease.How to be caused by virus, after antibacterial infects and is often secondary to viral infection.These disease four seasons, any age all can fall ill, and by containing the virulent spittle, droplet, or propagate through the apparatus polluting.Motherland's medical science is to infectious disease, particularly the understanding to respiratory infectious disease and prevent and treat with a long history.Before more than 2,000 years, Han dynasty Zhang Zhongjing just has relevant discussion to go out side by side the side's of control medicine.
Although it is of a great variety to treat in the market the Chinese patent medicine of upper respiratory tract infection disease, exist large such as dosage, effect duration is short, the inapparent problem of curative effect.
Summary of the invention
The object of the invention is: a kind of Chinese medicine composition that is used for the treatment of upper respiratory tract infection is provided.Technical scheme is:
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material by weight: 40～50 parts, Herba Ephedrae, 20～30 parts, Radix Glycyrrhizae, 20～40 parts of Radix Isatidis, 10～20 parts of Radix Bupleuri, 5～10 parts of the Rhizoma Pinelliaes, 5～10 parts of Radix Scutellariaes, 10～20 parts of Herba Taraxacis, 5～10 parts of Pericarpium Citri Reticulataes, 3～5 parts of Radix Platycodoniss, 4～8 parts of Mentholums, 3～5 parts of Radix Saposhnikoviaes, 6～12 parts of Fructus Forsythiaes, 10～15 parts of Flos Daturaes, 10～15 parts of Semen Sinapis Albaes, 30～50 parts, dextrin.
Herba Ephedrae has relievings asthma, and antitussive, removes expectorant, diaphoresis, and diuresis, antiinflammatory, antipyretic, the effect of excited maincenter.
Radix Glycyrrhizae is for asthma and cough.Can be alone, also can the application of compatibility other drug.As control the ERCHEN TANG of cough due to damp-phlegm; Control the Linggan Wuwei Jiangxin Tang of cold-phlegm cough with asthma; Control the sangxing decoction of dry stool phlegm cough; Control pyretic toxicity and cause the Radix Platycodonis decoction of the stench purulent sputum of lung abscess cough and spit; Control the Radix Glycyrrhizae Rhizoma Zingiberis soup of cough and spit saliva foam etc.The also Chang Peiwu application of another cough due to pathogenic wind-heat, cough due to wind and cold, phlegm heat cough.
Radix Isatidis has heat clearing away, removing toxic substances, removing heat from blood, effect of sore-throat relieving.
Effect that Radix Bupleuri has comprises: 1. antipyretic, effective ingredient: volatile oil (eugenol, acid, r-undecanoic acid lactone and to methoxybenzene diketone), saikoside (sapogenin A).Effect: heating due to typhoid fever, paratyphoid fever vaccine, escherichia coli liquid, fermented milk, yeast etc. is had to trivial solution heat effect; And can make animal normal body temperature decline.Saikosaponin decoct 2g/kg is to rabbit gavage, to all having obvious refrigeration function with the heating that vaccine and temperature thorn cause.2. antiinflammatory, effective ingredient: saponin.Effect: swollen and desmoplastic inflammation all has inhibitory action to ankle joint due to multiple proinflammatory agent.Saikoside 300mg/kg lumbar injection, can suppress the rat paw edema that carrageenin, 5-hydroxy tryptamine, histamine cause, suppresses rat granuloma swollen, can make adrenal gland's hypertrophy, atrophy of thymus gland simultaneously; Inflammation-inhibiting is organized histamine release and leukoplania.3. Promote immunity function, effective ingredient: Bupleurum chinense polysaccharide.Effect: phagocytic function strengthens, Natural killer activity strengthens, and improves special viral antibody titre, improves lymphocyte and turns core rate, improves skin delayed hypersensitivity reaction.
The Rhizoma Pinelliae can drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.Control damp-phlegm cold drink, vomiting, regurgitation, cough with asthma abundant expectoration, chest and diaphragm distension, syncope due to accumulation of phlegm headache, dizzy sleeplessness.Outer subduing inflammation., vomiting regurgitation dizzy for abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, interior expectorant, breast gastral cavity painful abdominal mass are vexed, globus hystericus disease; Raw with external treatment carbuncle sucutaneous nodule.Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) is used for stopping nausea and vomiting by lowering the adverse flow of QI.
Radix Scutellariae heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive, blood pressure lowering.For hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, cough due to lung-heat, high hot excessive thirst, heat in blood is told nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.
Herba Taraxaci heat-clearing and toxic substances removing, diuresis eliminating stagnation.Control acute mastitis, lymphadenitis, scrofula, furuncle carbuncle toxin, acute conjunctivitis, cold, fever, acute tonsillitis, acute bronchitis, gastritis, hepatitis, cholecystitis, urinary tract infection.
Pericarpium Citri Reticulatae regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.For fullness in the epigastrium and chest, lack of appetite and vomiting, cough with copious phlegm.
The functions such as Radix Platycodonis has lung qi dispersing, eliminates the phlegm, sore-throat relieving, evacuation of pus, cure mainly the symptom such as cough with copious phlegm, laryngopharynx swelling and pain.
Herba Menthae brain-capacity optionally stimulates the Cold receptor of human body skin or mucosa, produces sense of cold reflection and creeping chill, causes skin mucosa vasoconstriction (in fact skin keeps normal); Also can cause contraction to the blood vessel of deep tissue in addition, and produce therapeutical effect.External can antiinflammatory, pain relieving, and antipruritic, blood circulation promoting, alleviates edema etc.; For oral administration can alleviate local inflammation (pharyngolaryngitis) and treatment flu in compound preparation, and have stomach invigorating, wind dispelling effect.
Radix Saposhnikoviae expelling pathogenic wind from the body surface, removing dampness to relieve pain, spasmolytic, antipruritic.Cure mainly: affection of exogenous wind-cold; Headache general pain; Rheumatic arthralgia; Joint is ached; Stomachache is had loose bowels; Discharging fresh blood stool; Tetanus; Rubella pruritus; Skin infection from the beginning of.
The pharmacological action such as that Fructus Forsythiae has is antibacterial, heart tonifying, diuresis, town are told, is the Chinese medicine of heat-clearing and toxic substances removing, cures mainly calentura from the beginning of symptom, its bacteriostasis and Flos Lonicerae broadly similars such as, anemopyretic cold, heating, vexed, laryngopharynx swelling and pain, acute nephritis, carbuncle sore tumefacting virus.
Flos Daturae antiasthmatic-antitussive; Narcotic analgesic; Spasmolytic is only jerked.For asthma and cough; Coldness and pain in the epigastrium; Rheumatic arthralgia; Epilepsy; Infantile convulsion; Surgical anesthesia.
Semen Sinapis Albae warming the lung eliminating phlegm promoting the circulation of QI, mammary gland eliminating stagnation removing obstruction in the collateral to relieve pain.Breath with cough for cold-phlegm, distending pain in the chest and hypochondrium, the stagnant meridians of expectorant, joint numbness, pain, phlegm-damp oozing in the body, carbuncle of yin nature toxic swelling.
Another object of the present invention has been to provide a kind of preparation method of the above-mentioned pharmaceutical composition that is used for the treatment of upper respiratory tract infection, comprises the steps:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water of 10～12 times of above medical material gross weights, decoct 2～4 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 8～10 times of Rhizoma Pinelliae weight, decoct 1～3 hour, elimination residue, obtains lixiviating solution;
The 3rd step, get Mentholum, add the water of 8～10 times of Mentholum weight, decoct 0.5～1 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters, and obtains ultrafiltrate;
The 4th step, thick paste, lixiviating solution, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.25～1.39;
The 5th step, extract is mixed homogeneously with dextrin, granulate, dry, make.
In the 1st described step, the shared volume ratio of ethanol of ethanol water is 40%～50%.
The molecular cut off optimum of described ultrafilter membrane is 200,000～400,000.
In the 5th described step, granulation is to pass through wet granulation.
Beneficial effect
The present invention, by each herbal medicine synergism, can effectively treat the infection of upper respiratory tract, and alleviate malaise symptoms; Meanwhile, by the Rhizoma Pinelliae is separately extracted, effectively improve the extract yield of ephedrine, Mentholum has been processed by ultrafilter membrane, removed impurity, improved significantly the stability of finished product Ephedrine.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
Embodiment 1
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material: Herba Ephedrae 40kg, Radix Glycyrrhizae 20kg, Radix Isatidis 20kg, Radix Bupleuri 10kg, Rhizoma Pinelliae 5kg, Radix Scutellariae 5kg, Herba Taraxaci 10kg, Pericarpium Citri Reticulatae 5kg, Radix Platycodonis 3kg, Mentholum 4kg, Radix Saposhnikoviae 3kg, Fructus Forsythiae 6kg, Flos Daturae 10kg, Semen Sinapis Albae 10kg, dextrin 30kg.
Preparation method is:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water (the shared volume ratio of ethanol of ethanol water is 40%) of 10 times of above medical material gross weights, decoct 2 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 8 times of Rhizoma Pinelliae weight, decoct 1 hour, elimination residue, obtains lixiviating solution;
The 3rd step, get Mentholum, add the water of 8 times of Mentholum weight, decoct 0.5 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters (molecular cut off of ultrafilter membrane is 200,000), obtains ultrafiltrate;
The 4th step, thick paste, lixiviating solution, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.25;
The 5th step, extract is mixed homogeneously with dextrin, wet granulation, dry, make.
Embodiment 2
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material: Herba Ephedrae 50kg, Radix Glycyrrhizae 30kg, Radix Isatidis 40kg, Radix Bupleuri 20kg, Rhizoma Pinelliae 10kg, Radix Scutellariae 10kg, Herba Taraxaci 20kg, Pericarpium Citri Reticulatae 10kg, Radix Platycodonis 5kg, Mentholum 8kg, Radix Saposhnikoviae 5kg, Fructus Forsythiae 12kg, Flos Daturae 15kg, Semen Sinapis Albae 15kg, dextrin 50kg.
Preparation method is:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water (the shared volume ratio of ethanol of ethanol water is 50%) of 12 times of above medical material gross weights, decoct 4 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 10 times of Rhizoma Pinelliae weight, decoct 3 hours, elimination residue, obtains lixiviating solution;
The 3rd step, get Mentholum, add the water of 10 times of Mentholum weight, decoct 1 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters (molecular cut off of ultrafilter membrane is 400,000), obtains ultrafiltrate;
The 4th step, thick paste, lixiviating solution, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.39;
The 5th step, extract is mixed homogeneously with dextrin, wet granulation, dry, make.
Embodiment 3
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material: Herba Ephedrae 45kg, Radix Glycyrrhizae 25kg, Radix Isatidis 30kg, Radix Bupleuri 15kg, Rhizoma Pinelliae 7kg, Radix Scutellariae 7kg, Herba Taraxaci 15kg, Pericarpium Citri Reticulatae 7kg, Radix Platycodonis 4kg, Mentholum 6kg, Radix Saposhnikoviae 4kg, Fructus Forsythiae 8kg, Flos Daturae 12kg, Semen Sinapis Albae 12kg, DEXTRIN kg.
Preparation method is:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water (the shared volume ratio of ethanol of ethanol water is 45%) of 11 times of above medical material gross weights, decoct 3 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 9 times of Rhizoma Pinelliae weight, decoct 2 hours, elimination residue, obtains lixiviating solution;
The 3rd step, get Mentholum, add the water of 9 times of Mentholum weight, decoct 0.7 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters (molecular cut off of ultrafilter membrane is 300,000), obtains ultrafiltrate;
The 4th step, thick paste, lixiviating solution, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.30;
The 5th step, extract is mixed homogeneously with dextrin, wet granulation, dry, make.
Reference examples 1
Reference examples 1 is with the difference of embodiment 3: the Rhizoma Pinelliae extracts with other raw material in the 1st step simultaneously, particularly as follows:
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material: Herba Ephedrae 45kg, Radix Glycyrrhizae 25kg, Radix Isatidis 30kg, Radix Bupleuri 15kg, Rhizoma Pinelliae 7kg, Radix Scutellariae 7kg, Herba Taraxaci 15kg, Pericarpium Citri Reticulatae 7kg, Radix Platycodonis 4kg, Mentholum 6kg, Radix Saposhnikoviae 4kg, Fructus Forsythiae 8kg, Flos Daturae 12kg, Semen Sinapis Albae 12kg, DEXTRIN kg.
Preparation method is:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, the Rhizoma Pinelliae, add the ethanol water (the shared volume ratio of ethanol of ethanol water is 45%) of 11 times of above medical material gross weights, decoct 3 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get Mentholum, add the water of 9 times of Mentholum weight, decoct 0.7 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters (molecular cut off of ultrafilter membrane is 300,000), obtains ultrafiltrate;
The 3rd step, thick paste, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.30;
The 5th step, extract is mixed homogeneously with dextrin, wet granulation, dry, make.
Reference examples 2
Reference examples 2 is with the difference of embodiment 3: Mentholum, after decocting, does not filter by ultrafilter membrane, particularly refers to:
Be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material: Herba Ephedrae 45kg, Radix Glycyrrhizae 25kg, Radix Isatidis 30kg, Radix Bupleuri 15kg, Rhizoma Pinelliae 7kg, Radix Scutellariae 7kg, Herba Taraxaci 15kg, Pericarpium Citri Reticulatae 7kg, Radix Platycodonis 4kg, Mentholum 6kg, Radix Saposhnikoviae 4kg, Fructus Forsythiae 8kg, Flos Daturae 12kg, Semen Sinapis Albae 12kg, DEXTRIN kg.
Preparation method is:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water (the shared volume ratio of ethanol of ethanol water is 45%) of 11 times of above medical material gross weights, decoct 3 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 9 times of Rhizoma Pinelliae weight, decoct 2 hours, elimination residue, obtains lixiviating solution I;
The 3rd step, get Mentholum, add the water of 9 times of Mentholum weight, decoct 0.7 hour, elimination residue, obtains lixiviating solution II;
The 4th step, by thick paste, lixiviating solution I, lixiviating solution II, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.30;
The 5th step, extract is mixed homogeneously with dextrin, wet granulation, dry, make.
Content test
The HPLC detection method of the content (in ephedrine hydrochloride) of ephedrine is as follows:
According to high effective liquid chromatography for measuring, take octadecylsilane chemically bonded silica as filler, take acetonitrile-0.1% phosphoric acid solution (containing 0.1% triethylamine), (3:97) as mobile phase, detection wavelength is 205nm.Number of theoretical plate calculates and should be not less than 4000 by ephedrine hydrochloride.Get ephedrine hydrochloride reference substance appropriate, accurately weighed, the hydrochloric acid solution that adds 0.1mol/L is made the solution of every 1ml containing 45 μ g, obtains reference substance solution.Get this product under content uniformity item, porphyrize, gets 1g, accurately weighed, add 10ml distilled water and strong ammonia solution 0.5ml, with ether extraction 5 (30ml, 30ml, 20ml, 20ml, 20ml), merge ether solution, add ethanol solution hydrochloride (1 → 20) 2ml, mix, low temperature reclaims solvent to dry, and residue adds ethanol 5ml to be made to dissolve, and is transferred in 25ml measuring bottle, add 0.1mol/L hydrochloric acid solution and be diluted to scale, shake up, obtain need testing solution.Accurate reference substance solution and the each 10 μ l of need testing solution of drawing respectively, injection liquid chromatography, measures, and the results are shown in following table.
To carry out long-term stable experiment under listing terms of packing, 25 ℃ ± 2 ℃ of temperature, relative humidity, 60% ± 5%, samples respectively detection level at 0,3,6,9,12,18,24 the end of month.
Table 1 content and stability test result
| ? | Embodiment 1 | Embodiment 2 | Embodiment 3 | Reference examples 1 | Reference examples 2 |
| 0th month Content of Ephedrine With % (w/w) | 0.16 | 0.17 | 0.20 | 0.10 | 0.19 |
| Stable content % (w/w) | ? | ? | ? | ? | ? |
| 3 months | 0.16 | 0.17 | 0.20 | 0.09 | 0.17 |
| 6 months | 0.16 | 0.17 | 0.20 | 0.08 | 0.15 |
| 9 months | 0.15 | 0.16 | 0.20 | 0.08 | 0.14 |
| 12 months | 0.15 | 0.16 | 0.19 | 0.08 | 0.13 |
| 18 months | 0.15 | 0.16 | 0.19 | 0.07 | 0.12 |
| 24 months | 0.14 | 0.16 | 0.19 | 0.07 | 0.11 |
As can be seen from the table, in reference examples 1, because the Rhizoma Pinelliae is to extract with other component simultaneously, its ingredient containing has had influence on the leaching of ephedrine, makes its content lower; In reference examples 2, owing to Mentholum not being carried out to membrane separation for removing impurities, the impurity wherein containing is brought into product, had influence on the long-term storing stability of ephedrine, after the preservation of 24 months, the content of ephedrine declines obviously.
The test of pesticide effectiveness
1. separate heat test
Body weight 160-200g and body temperature are changed to the female rats random packet that is no more than 0.3 ℃, every group 10, gavage gives granule medicament (200mg/kg), aspirin 0.3g/kg (positive group) and the equivalent normal saline (matched group) of embodiment 1-3 gained respectively, after every Mus administration 30min in back subcutaneous injection 2,2, 4-dinitrophenol 1ml/100g (25mg/kg), respectively at after injection, 60,90,120,150,180min is measured in the same method each Mus anus temperature, result of the test is as shown in table 2.
Table 2 causes the impact of rat fever on 2,4-DNP
With relatively * p < 0.05 of model group
From table data can find out, the solution thermal effect of granule provided by the invention is better than positive group, and the successful of embodiment 3 is better than embodiment 1 and embodiment 2.
2. analgesic test
Get 40 of the female white mice of body weight 20 ± 2g, be divided at random: blank group (normal saline), positive drug group (aspirin 0.15g/kg), pharmaceutical composition high dose group of the present invention (200mg/kg), medicinal granule low dose group of the present invention (100mg/kg) is by after above-mentioned dosed administration, inject 0.6% glacial acetic acid 0.1mL/10g respectively at 30 minutes pneumoretroperitoneums, writhing number of times in 10 minutes after record injection algogen, statistical result is as shown in table 3.
Table 3 writhing number of times statistical result (X ± S)
| Group | Writhing number of times |
| Blank group | 51.3±4.7 |
| Positive drug group | 6.3±1.2* |
| High dose group | 12.4±2.1* |
| Low dose group | 17.8±2.3* |
With relatively * p < 0.05 of blank group
Result of the test shows that positive drug medicine group of the present invention and extract high dose group can significantly reduce the writhing response number of times of acetic acid induced mice, and low dose group can reduce the writhing response number of times of acetic acid induced mice, has good analgesia effect.
3. antiinflammatory test
Get body weight and be the male mice random packet of 23-26 gram, every group 10, gavage gives medicinal granule 200mg/kg of the present invention and 100mg/kg, prednisone 10mg/kg (positive group) and equivalent normal saline (matched group) respectively, once a day, continuous three days, be only evenly coated with dimethylbenzene 0.005ml/ to for after last administration 40 minutes the left ear of animal.Causing scorching latter 30 minutes execution animals, the rustless steel punching pin that is 8mm with diameter takes off left and right same area auricle, weighs, and is calculated as follows swelling and inhibitory rate of intumesce, and result is as shown in table 4.
Swelling=(left auricle weight-auris dextra sheet weight)
Inhibitory rate of intumesce=(1-administration group swelling/matched group swelling) × 100%
Table 4 xylol causes the impact of mice auricle swelling
| Group | Swelling (mg) | Suppression ratio % |
| Model group | 12.43±1.85 | ? |
| Positive drug group | 7.61±1.11* | 38.8 |
| High dose group | 8.26±1.23* | 33.5 |
| Low dose group | 8.44±1.32* | 32.1 |
With relatively * p < 0.05 of model group
Result demonstration, drug particles high dose group of the present invention, low dose group and prednisone group all can suppress xylene value mice ear, relatively have significant difference with matched group, show that pharmaceutical composition of the present invention has obvious antiinflammatory action.
4. In vitro Bactericidal Experiments
The part test result of the minimum inhibitory concentration (MIC) of pharmaceutical composition of the present invention is as shown in table 5-1 and table 5-2.
The MIC (mg/ml) (twice test meansigma methods) of table 5-1 to clinical isolates strain
| Clinical isolates strain | ? |
| Staphylococcus aureus | 2.5 |
| Escherichia coli | 5.0 |
| Diplococcus pneumoniae | >5.0 |
| Bacillus cloacae | 5.0 |
| Acinetobacter calcoaceticus | >5.0 |
| Kerekou pneumonia hundred Salmonellas | 2.5 |
| Streptococcus | 1.25 |
The MIC of table 5-2 to reference culture
| To reference culture | ? |
| Staphylococcus aureus | 2.5 |
| Escherichia coli | 5.0 |
| Bacillus pumilus | 5.0 |
| Bacillus subtilis | 5.0 |
| Micrococcus luteus | 2.5 |
Result shows: medicinal granule of the present invention all demonstrates and has certain bacteriostasis the common pathogen of clinical separation.
5. mice ammonia is drawn to the impact of coughing
Get 56 of male mouse of kunming, body weight 15-17g, be divided at random: blank group (normal saline), positive drug group benproperine phosphate 0.05g/kg), drug particles high dose group of the present invention (200mg/kg), drug particles low dose group of the present invention (100mg/kg) is by after above-mentioned dosed administration, administration volume is 20ml/kg body weight, mice is administration in batches, and 7 every batch, every group of each 1 mice.Each batch of mice accepted ammonia spraying in bell jar after 4 hours in administration, when spraying stops, take out immediately mice, then observes and record the number of times of coughing in the incubation period and 5 minutes of mouse cough.The results are shown in Table 6
Table 6 draws the impact (X ± S) of coughing incubation period and cough number of times due to mice ammonia
| Group | Incubation period (s) | Cough number of times (inferior/5min) |
| Blank group | - | 64.33±13.45 |
| Positive drug group | 51.3±12.4 | 7.32±3.42* |
| High dose group | 49.7±11.4 | 2.46±0.45* |
| Low dose group | 48.5±12.1 | 3.78±0.52* |
With relatively * p < 0.05 of blank group
Chinese medicine preparation of the present invention is used in 2006 to 2012 the routine patients of clinical observation upper respiratory tract infection 120, and clinical report is as follows:
1, physical data
In 120 routine patients, women's 60 examples, male's 60 examples, at minimum 7 years old of age, maximum 67 years old, the course of disease was many at 1 day to 7 days, 43.2 years old mean age.
2, diagnostic criteria
Reference " traditional Chinese medical science disease Standardization of diagnosis and curative effect ":
Primary symptom: (1) fever of the body, (2) aversion to wind; Inferior disease: (1) pharyngalgia, (2) are thirsty, (3) cough, (4) sweating, (5) nasal obstruction
Watery nasal discharge.The micro-Huang of thin white fur of tongue or BOHUANG, floating and rapid pulse or sliding number.Possess 2 of primary symptoms and time disease more than 2 or 2, possess above-mentioned tongue pulse condition person simultaneously.
3, Therapeutic Method
Granule, every day three times, each 10g, 5 days per courses for the treatment of
4, therapeutic outcome:
4.1 references " traditional Chinese medical science disease Standardization of diagnosis and curative effect ":
Cure: cardinal symptom, sign are alleviated completely or substantially, it is normal that objective indicator is recovered;
Effective: cardinal symptom, sign are obviously alleviated, objective indicator approaches normal;
Effective: cardinal symptom, sign take a turn for the better, and objective indicator makes moderate progress;
Invalid: cardinal symptom, sign are unchanged, objective indicator changes not obvious or increases the weight of.
4.2 results: in 120 routine patients, cure 95 examples (79.2%), effective 16 examples (13.3%), effective 7 examples (5.8%), invalid 2 examples (1.7%), total effective rate is 98.3%.
Below model case:
Case 1
Man, 8 years old, continuous three days sneeze, cough, taken the standing coldrex inefficacy of family, and have a fever the 4th day night suddenly, takes temperature 39.5 ℃.On inspection, this child's pars oralis pharyngis redness, antiadoncus is taken Chinese medicinal granule of the present invention in adopting the measure of control body temperature, takes two days, every day three times, each 10g, transference cure, recovers normal.
Case 2
Women, 36 years old, pharyngalgia, photophobia, sheds tears, and eye is itched, is generated heat, and 38.5 ℃ of body temperature check and find the obviously hyperemia of pharyngeal cavity and binding film, and routine blood test numeration of leukocyte reduces, and percentage of lymphocyte increases.Take Chinese medicinal granule provided by the invention, every day three times, each 10g, after 1 day, temperature recovery is normal, takes 3 days, and transference cure, recovers normal.
Claims (5)
1. be used for the treatment of a pharmaceutical composition for upper respiratory tract infection, include following raw material by weight: 40～50 parts, Herba Ephedrae, 20～30 parts, Radix Glycyrrhizae, 20～40 parts of Radix Isatidis, 10～20 parts of Radix Bupleuri, 5～10 parts of the Rhizoma Pinelliaes, 5～10 parts of Radix Scutellariaes, 10～20 parts of Herba Taraxacis, 5～10 parts of Pericarpium Citri Reticulataes, 3～5 parts of Radix Platycodoniss, 4～8 parts of Mentholums, 3～5 parts of Radix Saposhnikoviaes, 6～12 parts of Fructus Forsythiaes, 10～15 parts of Flos Daturaes, 10～15 parts of Semen Sinapis Albaes, 30～50 parts, dextrin.
2. a method of preparing the pharmaceutical composition that is used for the treatment of upper respiratory tract infection claimed in claim 1, comprises the steps:
The 1st step, get Herba Ephedrae, Radix Glycyrrhizae, Radix Isatidis, Radix Bupleuri, Radix Scutellariae, Herba Taraxaci, Pericarpium Citri Reticulatae, Radix Platycodonis, Radix Saposhnikoviae, Fructus Forsythiae, Flos Daturae, Semen Sinapis Albae, add the ethanol water of 10～12 times of above medical material gross weights, decoct 2～4 hours, after elimination residue, decocting liquid is reclaimed to ethanol, obtain thick paste;
The 2nd step, get the Rhizoma Pinelliae, add the water of 8～10 times of Rhizoma Pinelliae weight, decoct 1～3 hour, elimination residue, obtains lixiviating solution;
The 3rd step, get Mentholum, add the water of 8～10 times of Mentholum weight, decoct 0.5～1 hour, elimination residue, sends extracting solution into ultrafilter membrane and filters, and obtains ultrafiltrate;
The 4th step, thick paste, lixiviating solution, ultrafiltrate are merged, stir, be evaporated to the extract that the relative density at 80 ℃ is 1.25～1.39;
The 5th step, extract is mixed homogeneously with dextrin, granulate, dry, make.
3. the method for the pharmaceutical composition for the preparation for the treatment of upper respiratory tract infection according to claim 2, is characterized in that: in the 1st described step, the shared volume ratio of ethanol of ethanol water is 40%～50%.
4. the method for the pharmaceutical composition for the preparation for the treatment of upper respiratory tract infection according to claim 2, is characterized in that: the molecular cut off of described ultrafilter membrane is 200,000～400,000.
5. the method for the pharmaceutical composition for the preparation for the treatment of upper respiratory tract infection according to claim 2, is characterized in that: in the 5th described step, granulation is to pass through wet granulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410065107.4A CN103768308B (en) | 2014-02-25 | 2014-02-25 | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410065107.4A CN103768308B (en) | 2014-02-25 | 2014-02-25 | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103768308A true CN103768308A (en) | 2014-05-07 |
| CN103768308B CN103768308B (en) | 2016-05-04 |
Family
ID=50561368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410065107.4A Expired - Fee Related CN103768308B (en) | 2014-02-25 | 2014-02-25 | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768308B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721508A (en) * | 2015-03-15 | 2015-06-24 | 吉林大学 | Pharmaceutical composition for treating upper respiratory infection and preparation method thereof |
| CN105396114A (en) * | 2015-12-28 | 2016-03-16 | 刘树芹 | Medicine composition for treating respiratory tract infection |
| CN105617095A (en) * | 2016-01-27 | 2016-06-01 | 朱德密 | Oral liquid for acute upper respiratory infection in children and preparation method |
| CN105663258A (en) * | 2014-11-18 | 2016-06-15 | 郝建友 | Preparation method of injection for treating upper respiratory infection |
| CN105687335A (en) * | 2014-11-18 | 2016-06-22 | 郝建友 | Injection for treating upper respiratory tract infection |
| CN105770012A (en) * | 2014-11-18 | 2016-07-20 | 郝建友 | Preparation method of injection liquid for treating upper respiratory infection |
| CN106728164A (en) * | 2017-02-15 | 2017-05-31 | 成都市飞龙水处理技术研究所青白江第分所 | A kind of Chinese medicine composition for treating the infection of the upper respiratory tract and tonsillitis |
| WO2022217319A1 (en) * | 2021-04-14 | 2022-10-20 | Liquim Pty Ltd | Composition for prophylaxis against pathogens and methods of use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080156319A1 (en) * | 2005-06-02 | 2008-07-03 | Yuval Avni | Pulsating Inhaler and a Method of Treating Upper Respiratory Disorders |
| CN102380006A (en) * | 2011-10-18 | 2012-03-21 | 孙克勤 | Traditional Chinese medicine composition for treating upper respiratory tract infection |
| CN102641335A (en) * | 2012-05-21 | 2012-08-22 | 深圳市齐旺投资有限公司 | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof |
-
2014
- 2014-02-25 CN CN201410065107.4A patent/CN103768308B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080156319A1 (en) * | 2005-06-02 | 2008-07-03 | Yuval Avni | Pulsating Inhaler and a Method of Treating Upper Respiratory Disorders |
| CN102380006A (en) * | 2011-10-18 | 2012-03-21 | 孙克勤 | Traditional Chinese medicine composition for treating upper respiratory tract infection |
| CN102641335A (en) * | 2012-05-21 | 2012-08-22 | 深圳市齐旺投资有限公司 | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 汪受传: "小儿急性上呼吸道病毒感染中医诊疗指南", 《南京中医药大学学报》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663258A (en) * | 2014-11-18 | 2016-06-15 | 郝建友 | Preparation method of injection for treating upper respiratory infection |
| CN105687335A (en) * | 2014-11-18 | 2016-06-22 | 郝建友 | Injection for treating upper respiratory tract infection |
| CN105770012A (en) * | 2014-11-18 | 2016-07-20 | 郝建友 | Preparation method of injection liquid for treating upper respiratory infection |
| CN105853510A (en) * | 2014-11-18 | 2016-08-17 | 郝建友 | Injection for treating upper respiratory infection |
| CN104721508A (en) * | 2015-03-15 | 2015-06-24 | 吉林大学 | Pharmaceutical composition for treating upper respiratory infection and preparation method thereof |
| CN104721508B (en) * | 2015-03-15 | 2018-09-18 | 吉林大学 | A kind of pharmaceutical composition and preparation method for treating the infection of the upper respiratory tract |
| CN105396114A (en) * | 2015-12-28 | 2016-03-16 | 刘树芹 | Medicine composition for treating respiratory tract infection |
| CN105617095A (en) * | 2016-01-27 | 2016-06-01 | 朱德密 | Oral liquid for acute upper respiratory infection in children and preparation method |
| CN106728164A (en) * | 2017-02-15 | 2017-05-31 | 成都市飞龙水处理技术研究所青白江第分所 | A kind of Chinese medicine composition for treating the infection of the upper respiratory tract and tonsillitis |
| WO2022217319A1 (en) * | 2021-04-14 | 2022-10-20 | Liquim Pty Ltd | Composition for prophylaxis against pathogens and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103768308B (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308A (en) | Medicament composition for treating upper respiratory infections and preparation method thereof | |
| CN101181393A (en) | Chinese medicine preparation for curing common cold and producing method thereof | |
| US20230049291A1 (en) | Medicine for treating influenza or infectious diseases | |
| CN101411782A (en) | Pharmaceutical composition for treating acute pharyngitis and preparation method thereof | |
| CN109316551A (en) | A kind of Chinese medicine composition and preparation method thereof for treating acpuei pharyngitis | |
| CN105169017A (en) | Traditional Chinese medicine for treating kidney stone and preparation method of traditional Chinese medicine | |
| CN104547496A (en) | Traditional Chinese medicine composition for moistening lung to arrest cough and preparation method thereof | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| CN111358906B (en) | A kind of traditional Chinese medicine composition suitable for exopathy | |
| CN105267512A (en) | Medicine for treating upper respiratory tract infection | |
| CN104225026B (en) | Be used for the treatment of acute and chronic pharyngitis, upper respiratory tract infection, viral infection medicine | |
| CN103316086A (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN101837046A (en) | Anti-virus Chinese medicinal preparation and preparation method thereof | |
| CN104983968A (en) | Pyretolysis traditional Chinese medicine composition and preparation method | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN105343660A (en) | Traditional Chinese medicinal preparation for treating peripheral vertigo and preparation method of traditional Chinese medicinal preparation | |
| CN104623379B (en) | A kind of pharmaceutical composition for treating children's hand-foot-mouth disease | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN103816281A (en) | Traditional Chinese medicine composition for preventing and treating wind-heat common cold | |
| CN103463399B (en) | Medicament for treating infantile asthma and preparation method thereof | |
| CN103705599B (en) | A kind of pharmaceutical composition for the treatment of cough and preparation method thereof | |
| CN1931262B (en) | Common cold treating Chinese medicine preparation | |
| CN103463537B (en) | Medicament for treating infantile asthma | |
| CN103599442A (en) | Novel method for preparing pharyngitis tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160504 Termination date: 20170225 |